ACHN News 9.47 08/22/2014 04:23:50 Achillion Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board

Aug 22, 2014 at 5:23 AM

Achillion Pharmaceuticals (ACHN) 9.47 $ACHN

Achillion Attains 52-Week High on ACH-3102 Patent Protection - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 4:00PM CDT
Achillion's (ACHN) shares touched a 52-week high of $10.18 on Aug 20 following its announcement that the USPTO has granted a patent to the company.

The Zacks Analyst Blog Highlights: Achillion Pharmaceuticals, Gilead Sciences, Amgen, Roche and Biogen
PR Newswire - Thu Aug 21, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN-Free Report), Gilead Sciences (Nasdaq:GILD-Free Report), Amgen (Nasdaq:AMGN-Free Report), Roche (OTC:RHHBY-Free Report) and Biogen (Nasdaq:BIIB-Free Report).

Healthcare Enjoys Growth Trends: 3 Medical Stocks to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 3:27PM CDT
Favorable industry trends in the pharma and bio-tech space makes the healthcare sector a lucrative investment destination.

Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 20, 10:08AM CDT
Last week, hepatitis C virus treatments remained in focus with Achillion and Gilead providing updates on ACH-3102 and Sovaldi, respectively.

Biotechnology Stocks to Keep an Eye On
ACCESSWIRE - Wed Aug 20, 8:01AM CDT
Deerfield Beach, FL / Aug 20, 2014 / It has been a disappointing year for biotechnology stocks so far after last year's surge. The correction was expected after last year's surge; however, the losses were accentuated after Fed Chair Janet Yellen's comments earlier this year regarding a possible bubble in biotech and social media stocks.

New Drug Launches, Technical Updates, New Facility, Clinical Trials Data, and Dividend Declarations - Research Reports on Covidien, Mylan, Baxter, Achillion and Perrigo
PR Newswire - Wed Aug 20, 7:40AM CDT
Today, Analysts Review released its research reports regarding Covidien PLC (NYSE: COV), Mylan, Inc. (NASDAQ: MYL), Baxter International Inc. (NYSE: BAX), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) and Perrigo Company PLC (NYSE: PRGO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5849-100free.

ACHILLION PHARMA
at Investor's Business Daily - Tue Aug 19, 5:47PM CDT
ACHILLION PHARMA (ACHN) got a patent OK for ACH-3102, its hepatitis C treatment. Shares rose 2.8% after closing up 3.5%.

Why Achillion Pharmaceuticals (ACHN) Stock Is Up in After-Hours Trading Today
at The Street - Tue Aug 19, 3:45PM CDT
Achillion Pharmaceuticals (ACHN) rose in after-hours trading Tuesday after the company received a patent for its hepatitis C drug ACH-3102.

Achillion Granted U.S. Patent for ACH-3102 and Structurally Related NS5A Inhibitors
GlobeNewswire - Tue Aug 19, 3:05PM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent & Trademark Office has granted Achillion U.S. Patent No. 8,809,313, covering composition-of-matter and method of use claims for ACH-3102 and structurally related NS5A inhibitor compounds. ACH-3102 is Achillion's second generation Phase 2 NS5A inhibitor being investigated for the treatment of chronic hepatitis C virus (HCV) infection. This patent is entitled "Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections," and provides a patent term which lasts until 2032.

Can The Uptrend Continue for Achillion (ACHN)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 6:57AM CDT
Can The Uptrend Continue for Achillion (ACHN)?

Achillion Pharmaceuticals
at Investor's Business Daily - Mon Aug 18, 5:40PM CDT
Achillion Pharmaceuticals (ACHN) was upgraded to buy from hold by Deutsche Bank, and its price target was raised to 17 from 6 on good news about its new hepatitis drug. Shares rose 3.1% to 9.5.

Achillion Pharmaceuticals Soars on Mid-Stage HCV Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 3:45PM CDT
Achillion Pharmaceuticals (ACHN) reported positive interim results from a phase II study on ACH-3102.

Should Achillion Pharma (ACHN) Be In Your Portfolio Now? - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Mon Aug 18, 2:20PM CDT
ACHN is soaring today, but have investors already missed all the big gains?

Achillion Pharmaceuticals Up On Buyout Rumors
at Investor's Business Daily - Mon Aug 18, 12:52PM CDT
Achillion Pharmaceuticals (ACHN) stock touched an 18-month high for the second straight trading day on Monday, after Deutsche Bank upgraded the biotech startup and boosted price target on positive news about its new hepatitis drug. Achillion stock...

3 Big Stocks on Traders' Radars
at The Street - Mon Aug 18, 11:02AM CDT
Here's how to trade some of the most active stocks on the market today.

Why Achillion Pharmaceuticals (ACHN) Stock Hit a One-Year High Today
at The Street - Mon Aug 18, 9:12AM CDT
Achillion Pharmaceuticals (ACHN) hit a 52-week high of $10.10 on Monday after Deutsche upgraded the stock and increased its price target 183%.

Achillion Pharmaceuticals (ACHN) in Focus: Stock Up 9.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 7:44AM CDT
Achillion Pharmaceuticals (ACHN) was a big mover last session, as the company saw its shares gain nearly 10% on the day.

Nasdaq stocks posting largest percentage increases
AP - Fri Aug 15, 5:16PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:

Gilead Wins Sovaldi Dispute With Roche, U.K. Nod
at Investor's Business Daily - Fri Aug 15, 4:44PM CDT
Big-cap biotech Gilead Sciences (GILD) rose 3.2% to 99.49 on the stock market today, hitting a new all-time high Friday after it won a dispute with Roche over rights to its blockbuster hepatitis C drug, which separately was endorsed by the U.K.'s...

Why Achillion Pharmaceuticals, Inc. Stock Soared
Sean Williams, The Motley Fool - Motley Fool - Fri Aug 15, 1:50PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Achillion Pharmaceuticals , a...

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

21st.BIO Seeks EU Nod for Precision Fermentation Tech

Is Precision Fermentation Europe's Next Big Bet? Here we go again with another tech trying to revolutionize the food industry, and this time it's the Danish company 21st.BIO making strides in Europe. They've tossed their hat in the ring with an EU Novel Food application for BLG Essential+™, hoping to weave precision fermentation into the fabric of European food...

Aristocrat's Leadership Shift: Croker to Guisard in 2027

Aristocrat's Upcoming Change at the Helm Shuffling the deck at the top can make or break a ship. Aristocrat is swapping its captain as Trevor Croker steps down, and they're betting Dafne Guisard's got the wind in her sails to ride the next wave. This ain't your average CEO transition, either—it's got a whole year of easing into the reins. The Decision to Appoint Guisard...

Global Challenge: A New Era for AI Web Agents

By Riley Hayes Updated Nov 12, 2026 Category News Views 118

The Dawn of the Agent Web Well, here we are, standing at the cusp of a new digital frontier, folks. This ain't just another buzzword parade; this is the Open Agentic Web Challenge, courting developers with a $13K carrot to craft an interoperable playground for AI agents. Big names like Cognizant AI Lab, MIT Media Lab, and others are leading the charge. No small-time...

Reolink Slashes Prices for Black Friday Bonanza

Security Steals: Navigating Reolink's Festive Deals Well, folks, if you're in the market for sprucing up your security game, this might just be your lucky season. Reolink, a name folks trust when it comes to security gadgets, is dropping the hammer with some serious Black Friday and Cyber Monday discounts. Starting November 12, they're setting the stage for nearly three...

Clean Tech's Dual Role: Energy Resilience and Dependency

Technology's Double-Edged Sword in Energy You ever chat with someone about moving your whole life onto solar? Seems greener and cheaper, right? But dive into the numbers, and you'll see it comes with its own set of strings attached. According to a fresh-off-the-press report from S&P Global, clean tech is both a saving grace and a looming liability economically and...

Lucas Bols: A Legacy Crowned A 450-year-old legacy finally gets its due with the Lucas Bols Company snagging the "Spirit Brand of the Year" title from Wine Enthusiast. This ain’t just another pat on the back; it's a serious nod to a brand that’s been laying down the cocktail foundation long before some countries even existed. Across the past five centuries, they've...

FCM Travel Names New CPO to Lead AI Innovation

Fresh Face at the Helm Hiring Mark McSpadden as Chief Product Officer is a move by FCM Travel that signals the company's intent to deepen its roots in tech and innovation within the corporate travel sector. There's no subtlety here—FCM's making a bold statement, and they're throwing serious weight behind their tech strategy. Don’t take this lightly; this is them...

THE HONEST FARMER Risks Launch into China's Market

THE HONEST FARMER Challenges Mainland China Okay, let's tackle this little tangent in the ever-evolving saga of food exports. THE HONEST FARMER Co., Ltd., a name probably unfamiliar to many unless you're tuning into South Korea's food manufacturing scene, is stirring the pot by diving into unfamiliar waters—mainland China. They're leaning heavily on their in-house...

Southwest Airlines' 191st Quarterly Dividend: A Steady Flight

Another Dividend in Southwest’s Long-Running Playbook Well, here we go again, folks. Southwest Airlines (NYSE: LUV) has just waved the flag on their 191st quarterly dividend like clockwork, pegged at $0.18 per share. If you’re into steady-as-she-goes stock scenarios, this is your scene. On December 17, 2026, registered shareholders are gonna see that little bump in...

Hornets Expand 5G Network Across New Performance Center

Boosting Connectivity with Boldyn Networks Well, the Charlotte Hornets are making moves, folks—beyond just the basketball court. Their play isn't a buzzer-beater this time but a calculated strategy to slap a 5G facelift onto their domain. Partnering with Boldyn Networks, they've spun a web of high-performance cellular sparks across both the Spectrum Center and their...